Plasminogen activator inhibitor-1 (PAI-1)
Plasminogen activator inhibitor (PAI-1; EC 3.4.21.68) a serine protease inhibitor, is involved in numerous processes including thrombosis and fibrosis. Its inhibition may thus yield important cardio- and reno-protective benefits. Studies in mice overexpressing human PAI-1 also implicate its involvement in broader biological abnormalities, including alopecia, amyloidosis, and polycystic ovarian syndrome[1].
[1] Y. Izuhara et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J. Cereb. Blood Flow Metab. 2010, 30, 904-912.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3590 | ACT001 | PAI-1 inhibitor | €210.00 | |
| 3710 | PAZ-417 | Potent, orally active and CNS-penetrant PAI-1 inhibitor | €130.00 | |
| 2838 | SK-216 | Specific inhibitor of PAI-1 | €105.00 | |
| 1769 | T 1776Na | Inhibitor of plasminogen activator inhibitor-1 | €80.00 | |
| 1383 | Tiplaxtinin | Plasminogen activator inhibitor-1 (PAI-1) inhibitor | €70.00 | |
| 2344 | TM 5275 | Selective and orally active inhibitor of PAI-1 | €105.00 | |
| 2734 | TM 5441 | Orally active inhibitor of PAI-1 | €105.00 | |